|
PIGA expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.32450000026141E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.61590000000401E-05 |
| Normal-vs-Stage2 |
1.51039999995994E-06 |
| Normal-vs-Stage3 |
2.66660000003416E-06 |
| Normal-vs-Stage4 |
4.42960000002213E-06 |
| Stage1-vs-Stage2 |
2.976300E-02 |
| Stage1-vs-Stage3 |
8.509700E-02 |
| Stage1-vs-Stage4 |
1.029650E-01 |
| Stage2-vs-Stage3 |
4.172800E-01 |
| Stage2-vs-Stage4 |
4.740200E-01 |
| Stage3-vs-Stage4 |
9.468800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.27889999998765E-06 |
| Normal-vs-AfricanAmerican |
1.505720E-02 |
| Normal-vs-Asian |
4.962700E-04 |
| Caucasian-vs-AfricanAmerican |
8.214800E-01 |
| Caucasian-vs-Asian |
5.390800E-01 |
| AfricanAmerican-vs-Asian |
5.750600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.50528999999233E-05 |
| Normal-vs-Female |
2.17619999998142E-06 |
| Male-vs-Female |
4.004000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.437200E-04 |
| Normal-vs-Age(41-60Yrs) |
3.5589000002556E-07 |
| Normal-vs-Age(61-80Yrs) |
4.0107999998984E-07 |
| Normal-vs-Age(81-100Yrs) |
1.728020E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.838500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.138200E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.018600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.810000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.347600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.857820E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.443200E-01 |
| Classical-VS-Follicular |
3.083000E-03 |
| Classical-VS-Other |
9.870600E-01 |
| Classical-VS-Normal |
2.26019999999272E-05 |
| Tall-VS-Follicular |
2.195000E-01 |
| Tall-VS-Other |
6.616600E-01 |
| Tall-VS-Normal |
3.369200E-04 |
| Follicular-VS-Other |
3.799200E-01 |
| Follicular-VS-Normal |
4.29600000018127E-07 |
| Other-VS-Normal |
1.267420E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.9800999995212E-07 |
| Normal-vs-N1 |
5.54010000000105E-05 |
| N0-vs-N1 |
1.997780E-01 |
|
|
